8-K
filed June 21, 2023, 7:59 PM ET
ticker ICCC
CIK 0000811641
other material
confidence high
sentiment neutral
materiality 0.40
ImmuCell appoints Bryan Gathagan to board; board extends rights plan despite advisory vote failure
IMMUCELL CORP /DE/
- Bryan K. Gathagan appointed independent director effective June 16, 2023; appointed to Audit Committee.
- Non-binding advisory vote on extending rights plan by one year failed with 42% of shares present, but 65% of votes cast in favor.
- Board extended Common Stock Rights Plan to September 19, 2024 despite advisory vote failure.
- All six director nominees elected; Wipfli LLP ratified as auditor for FY2023.
- 5.7M shares represented (73% of outstanding) at annual meeting.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Bryan K. Gathagan was elected as independent director at IMMUCELL CORP /DE/.
- Action
- elected
- Role
- independent director
Exact text from the filing
Pursuant to a recommendation by the Nominating Committee, the board of directors (the “Board”) of ImmuCell Corporation (the “Company”) elected Mr. Bryan K. Gathagan as an independent director, effective June 16, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
IMMUCELL CORP /DE/ shareholders approved To approve a non-binding advisory resolution on the Company’s executive compensation program. at the 2023-06-15 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
2. To approve a non-binding advisory resolution on the Company’s executive compensation program: For Against Abstain Broker Non-votes 3,293,046 76,241 303,370 2,032,888
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
IMMUCELL CORP /DE/ shareholders approved To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2023. at the 2023-06-15 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
4. To ratify the Audit Committee’s selection of Wipfli LLP as the Independent Registered Public Accounting Firm of the Company for the year ending December 31, 2023: For Against Abstain Broker Non-votes 5,687,633 9,343 8,569 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
IMMUCELL CORP /DE/ shareholders approved To elect to one-year terms as Directors of the Company the six nominees listed in the 2023 Proxy Statement. at the 2023-06-15 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
1. To elect to one-year terms as Directors of the Company the nominees listed in the Company’s Proxy Statement dated April 28, 2023: For Withheld Broker Non-votes Gloria J. Basse 3,594,248 78,409 2,032,888 Michael F. Brigham 3,590,547 82,110 2,032,888 Bobbi Jo Brockmann 3,614,602 58,055 2,032,888 Steven T. Rosgen 3,592,944 79,713 2,032,888 David S. Tomsche 3,555,331 117,326 2,032,888 Paul R. Wainman 3,547,166 125,491 2,032,888
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
IMMUCELL CORP /DE/ shareholders rejected To approve a non-binding advisory vote on whether to amend the Company’s Common Stock Rights Plan extending its expiration date by one year to September 19, 2024. at the 2023-06-15 meeting.
- Proposal
- say on pay
- Outcome
- failed
- Meeting
- 2023-06-15
Exact text from the filing
3. To approve a non-binding advisory vote on whether to amend the Company’s Common Stock Rights Plan extending its expiration by one year to September 19, 2024: For Against Abstain Broker Non-votes 2,390,931 1,270,796 10,930 2,032,888
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.